naa a22 4500 510779891 CHVBK 20180411083243.0 cr unu---uuuuu 180411e20131001xx s 000 0 eng 10.1007/s11892-013-0414-8 doi (NATIONALLICENCE)springer-10.1007/s11892-013-0414-8 Biologic Agents in Islet Transplantation [Elektronische Daten] [Boris Gala-Lopez, Andrew Pepper, A. Shapiro] Islet transplantation is today an accepted modality for treating selected patients with frequent hypoglycemic events or severe glycemic lability. Despite tremendous progress in islet isolation, culture, and preservation, clinical use is still restricted to a limited subset, and lifelong immunosuppression is required. Issues surrounding limited islet revascularization and immune destruction remain. One of the major challenges is to prevent alloreactivity and recurrence of autoimmunity against β-cells. These two hurdles can be effectively reduced by immunosuppressive therapy combining induction and maintenance treatments. The introduction of highly potent and selective biologic agents has significantly reduced the frequency of acute rejection and has prolonged graft survival, while minimizing the complications of this therapeutic scheme. This review will address the most important biological agents used in islet transplantation. We provide a historical perspective of their introduction into clinical practice and their role in current clinical protocols, aiming at improved engraftment efficiency, increased long-term survival, and better overall results of clinical islet transplantation. Springer Science+Business Media New York, 2013 Islet transplantation nationallicence Immunosuppression nationallicence Biologic agents nationallicence Antibodies nationallicence Induction strategies nationallicence Maintenance schemes nationallicence Immune response nationallicence Acute rejection nationallicence Graft survival nationallicence IT : Islet transplant nationallicence IS : Immunosuppression nationallicence ICAM-1 : Intercellular Adhesion Molecule-1 nationallicence IL : Interleukin nationallicence T1DM : Type 1 diabetes mellitus nationallicence CNI : Calcineurin inhibitor nationallicence MMF : mycophenolate mofetil nationallicence mTOR : mammalian target of rapamycin nationallicence ATG : Anti-thymocyte globulin nationallicence IgG1 : Immunoglobulin G1 nationallicence CTLA-4 : Cytotoxic T-lymphocyte antigen 4 nationallicence LFA : Leukocyte Function Antigen nationallicence mAb : Monoclonal antibody nationallicence TCR : T-cell receptor nationallicence BAFF-R : BAAF receptor nationallicence GLP-1 : Glucagon-like peptide 1 nationallicence Gala-Lopez Boris Clinical Islet Transplant Program and Department of Surgery, University of Alberta, Edmonton, AB, Canada aut Pepper Andrew Clinical Islet Transplant Program and Department of Surgery, University of Alberta, Edmonton, AB, Canada aut Shapiro A. Clinical Islet Transplant Program and Department of Surgery, University of Alberta, Edmonton, AB, Canada aut Current Diabetes Reports Springer US; http://www.springer-ny.com 13/5(2013-10-01), 713-722 1534-4827 13:5<713 2013 13 11892 https://doi.org/10.1007/s11892-013-0414-8 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11892-013-0414-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Gala-Lopez Boris Clinical Islet Transplant Program and Department of Surgery, University of Alberta, Edmonton, AB, Canada aut NATIONALLICENCE 700 1- Pepper Andrew Clinical Islet Transplant Program and Department of Surgery, University of Alberta, Edmonton, AB, Canada aut NATIONALLICENCE 700 1- Shapiro A. Clinical Islet Transplant Program and Department of Surgery, University of Alberta, Edmonton, AB, Canada aut NATIONALLICENCE 773 0- Current Diabetes Reports Springer US; http://www.springer-ny.com 13/5(2013-10-01), 713-722 1534-4827 13:5<713 2013 13 11892 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer